PMID: 11920534Mar 29, 2002Paper

The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease

Cancer
Francesco DiRaimondoM Keating

Abstract

CD23 antigen is a cell surface protein considered important in the differentiation of chronic lymphocytic leukemia (CLL) from other lymphoid leukemias. To better clarify CD23 role as a diagnostic tool, the authors retrospectively evaluated clinical and laboratory features of 372 patients who were referred to M.D. Anderson Cancer Center with a diagnosis of CLL or B-cell chronic lymphoproliferative disease. Most of the patients (91%) were CD19+/CD5+. Only 6% of these CD19+/CD5+ patients were CD23-. Overall, CD23- patients had the worse prognostic features compared with CD23+ cases, including anemia (P = 0.03), massive splenomegaly (P = 0.000), high lactate dehydrogenase (P = 0.007), high beta2-microglobulin (P = 0.006), older age (P = 0.001), and male gender (P = 0.02). Surface immunoglobulin expression was moderate/strong in 19 (82%) patients, and FMC-7 was positive in 22 (96%) patients. None of the 13 patients tested for CD10 expressed the antigen. Based on morphology, of the CD23, 16 (70%) were diagnosed with mantle cell leukemia (MCL) was diagnosed in 16 (70%) CD23- patients, 3 (13%) with splenic marginal-zone leukemia, 3 (13%) with prolymphocytic leukemia (PLL) or PLL/CLL, and 1 (4%) with CLL. No cyclin D1 protein expression...Continue Reading

References

May 1, 1979·Scandinavian Journal of Haematology·G PallesenB B Pedersen
Sep 1, 1992·Genes, Chromosomes & Cancer·V Brito-BabapulleD Catovsky
Apr 1, 1992·The Journal of Clinical Investigation·S FournierM Sarfati
Aug 1, 1989·British Journal of Haematology·J GibsonH Kronenberg
Feb 1, 1995·British Journal of Haematology·S FournierM Sarfati
Mar 1, 1993·Blood Reviews·H F BarkerI M Franklin
May 1, 1996·The American Journal of Surgical Pathology·S H SwerdlowM E Williams
Nov 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S Multani, M L Grossbard
Dec 16, 1998·Ryōikibetsu shōkōgun shirīzu·T Hayashi, Y Nonaka

❮ Previous
Next ❯

Citations

Oct 4, 2002·Hematological Oncology
Jan 14, 2004·Proceedings of the National Academy of Sciences of the United States of America·Vijay P S RawatChristian Buske
Jun 12, 2003·Current Opinion in Hematology·Thomas J Kipps
Mar 17, 2006·Applied Immunohistochemistry & Molecular Morphology : AIMM·Sheila Aparecida Coelho SiqueiraPaulo Hilario Nascimento Saldiva
Jan 17, 2008·Blood·Fiona E Craig, Kenneth A Foon
Feb 8, 2003·The Lancet Oncology·Catherine ThieblemontBertrand Coiffier
Dec 29, 2004·Leukemia & Lymphoma·J D SchwarzmeierM Shehata
Jul 31, 2007·Clinics in Laboratory Medicine·Fiona E Craig
Apr 3, 2008·Hematological Oncology·Gábor BarnaAndrás Matolcsy
Apr 30, 2003·Expert Opinion on Biological Therapy·Arthur E FrankelRonald Gartenhaus
Apr 6, 2016·The Korean Journal of Internal Medicine·Young-Woo Jeon, Seok-Goo Cho
Sep 16, 2016·Internal Medicine·Shigeki ShimizuShinji Atagi
Dec 20, 2008·American Journal of Clinical Pathology·Albert K HoDavid W Bahler
Apr 12, 2003·Leukemia & Lymphoma·Giovanni D'ArenaMichael J Keating
Dec 31, 2020·Cells·Laura GragnaniAnna Linda Zignego
Mar 6, 2008·Archives of Pathology & Laboratory Medicine·Russell A HigginsMarsha C Kinney
Feb 23, 2021·Case Reports in Gastroenterology·Ahmed M Ahmed, Sima Vossough

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.